CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
CCNE1 overexpression	Breast Cancer	CCNE1 overexpression	Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
HR positive + CCNE1 overexpression	HER2 Negative Breast Cancer	HR positive + CCNE1 overexpression	HER2 Negative Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
CCNE1 amplification	Solid Tumor	CCNE1 amplification	Solid Tumor	RP-6306 Sensitive: C2 – Inclusion Criteria RP-6306 Sensitive : C2	RP-6306 Sensitive: C2 – Inclusion Criteria RP-6306 Sensitive : C2
CCNE1 overexpression	Ovarian Cancer	CCNE1 overexpression	Ovarian Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	RP-6306 Sensitive: C2 – Inclusion Criteria RP-6306 Sensitive : C2	RP-6306 Sensitive: C2 – Inclusion Criteria RP-6306 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	BLU-222 Sensitive: C2 – Inclusion Criteria BLU-222 Sensitive : C2	BLU-222 Sensitive: C2 – Inclusion Criteria BLU-222 Sensitive : C2
CCNE1 amplification	Solid Tumor	CCNE1 amplification	Solid Tumor	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	INX-315 Sensitive: C2 – Inclusion Criteria INX-315 Sensitive : C2	INX-315 Sensitive: C2 – Inclusion Criteria INX-315 Sensitive : C2
CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer	CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CCNE1 expression	Estrogen Receptor Positive Breast Cancer	CCNE1 expression	Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CCNE1 overexpression + PIK3CA muattion + ER positive	HER2 Negative Breast Cancer	CCNE1 overexpression + PIK3CA muattion + ER positive	HER2 Negative Breast Cancer	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3

CCNE1 (Cyclin E1)

Associations(36)

Associations
(36)